
|Articles|June 1, 2005
Squalamine lactate preserves vision in phase II trial
Key Biscayne, FL—In a small, phase II clinical trial of squalamine lactate (Evizon, Genaera Corp.), a systemically delivered drug for the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), all patients who received a 40-mg dose had preserved or improved vision through a 4-month study period, reported Carl Regillo, MD, FACS.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
2
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease
3
Strategic approaches optimize teaching and learning in the clinic
4
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
5












































.png)


